Skip to main content

Table 6 Nutrition- and inflammation-based markers of patients with SMIHigh and SMILow UGC

From: Impact of skeletal muscle mass in patients with unresectable gastric cancer who received palliative first-line chemotherapy based on 5-fluorouracil

 

SMIHigh (n = 41)

SMILow (n = 42)

P value

CRP

0.789 ± 0.928

1.273 ± 2.731

0.245

Albumin

3.7 ± 0.5

3.5 ± 0.7

0.296

PNI

45.05 ± 5.73

42.4 ± 8.7

0.108

NLR

2.567 ± 1.081

4.110 ± 4.560

0.047

CAR

0.220 ± 0.255

0.514 ± 1.264

0.308

PLR

189.0 ± 103.7

224.9 ± 135.2

0.226

CEA

18.3 ± 49.1

16.7 ± 38.4

0.604

CA19–9

334.9 ± 1198.2

111.6 ± 416.2

0.610

  1. Data are presented as the mean ± standard deviation or number (percentage) of patients
  2. CA19–9, carbohydrate antigen; CEA, carcinoembryonic antigen; CRP, C-reactive protein; CAR, C-reactive protein-to-albumin ratio; NLR, neutrophil to lymphocyte ratio; PLR, platelet to lymphocyte ratio; PNI, the prognostic nutritional index; SMIHigh, high skeletal muscle mass; SMILow, low skeletal muscle mass; UGC, unresectable gastric cancer